BMS Reyataz complaint presages easier exclusivity enforcement in 'tricky' markets?
This article was originally published in Scrip
Executive Summary
Voluntary license agreements could become an increasingly popular means for originator companies to protect brand exclusivity in global markets where there is money to be made but little protection for intellectual property rights. A breach of contract complaint brought by Bristol-Myers Squibb in the US against Mylan/Matrix will put the theory to the test.